ADPTAdaptive Biotechnologies Corporation

$26.49+98% 1Y

Is the price fair?

What ADPT's price assumes

Adaptive Biotechnologies Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 10.5× revenue.

10.5

Price / sales · no P/E: the last twelve months did not end in a profit

Price / book
22.7

Price / book · today's price, trailing year to Jun 30, 2026

EV / sales
9.40

EV / sales

Details›
Price / booktoday's price, trailing year to Jun 30, 2026
22.7
EV / EBIToperating margin −12%: the multiple describes the denominator
not meaningful
EV / salestoday's price, trailing year to Jun 30, 2026
9.40
Market capitalisation
$3.24B

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.